- Home
- ICLR vs FDS Comparison
ICLR vs FDS Comparison
Compare ICLR & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- FDS
- Stock Information
- Founded
- ICLR 1990
- FDS 1978
- Country
- ICLR Ireland
- FDS United States
- Employees
- ICLR N/A
- FDS N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- FDS Computer Software: Programming Data Processing
- Sector
- ICLR Health Care
- FDS Technology
- Exchange
- ICLR Nasdaq
- FDS Nasdaq
- Market Cap
- ICLR 15.7B
- FDS 17.4B
- IPO Year
- ICLR 1998
- FDS 1996
- Fundamental
- Price
- ICLR $214.25
- FDS $487.39
- Analyst Decision
- ICLR Strong Buy
- FDS Sell
- Analyst Count
- ICLR 10
- FDS 14
- Target Price
- ICLR $290.60
- FDS $455.54
- AVG Volume (30 Days)
- ICLR 1.9M
- FDS 256.5K
- Earning Date
- ICLR 10-23-2024
- FDS 12-19-2024
- Dividend Yield
- ICLR N/A
- FDS 0.85%
- EPS Growth
- ICLR 44.49
- FDS 15.53
- EPS
- ICLR 8.99
- FDS 13.91
- Revenue
- ICLR $8,306,823,000.00
- FDS $2,203,056,000.00
- Revenue This Year
- ICLR $4.00
- FDS $5.49
- Revenue Next Year
- ICLR $3.16
- FDS $5.90
- P/E Ratio
- ICLR $23.84
- FDS $35.06
- Revenue Growth
- ICLR 3.63
- FDS 5.64
- 52 Week Low
- ICLR $183.38
- FDS $391.84
- 52 Week High
- ICLR $347.72
- FDS $499.87
- Technical
- Relative Strength Index (RSI)
- ICLR 41.76
- FDS 60.35
- Support Level
- ICLR $183.38
- FDS $472.24
- Resistance Level
- ICLR $217.91
- FDS $499.87
- Average True Range (ATR)
- ICLR 8.58
- FDS 9.35
- MACD
- ICLR 2.86
- FDS 0.01
- Stochastic Oscillator
- ICLR 63.64
- FDS 67.68
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.